In vitro and preclinical studies have demonstrated that SGLT2 inhibitors can slow tumor growth in prostate cancer. For example, canagliflozin has been shown to suppress the proliferation of prostate cancer cells and to enhance their response to chemotherapy and radiotherapy, whereas dapagliflozin lacked such effects in the same models. Such anticancer activity provides a plausible mechanism for the delayed progression observed in patients treated with SGLT2 inhibitors in this study. This evidence concerns the gene SLC5A2 and prostate cancer.